16th August 2019
Sleepify selected for the Go2China programme in Shenzhen
We met Rasmus Nilsson, CEO of the Swedish medtech company Sleepify, accelerated by EIT Health, who told us all about one of the most fundamental needs of human beings – sleep – and about the unique heavy-weight sleeping blankets that his company have developed to cure sleeping disorders related to neuropsychological dysfunctions, stress and anxiety. Thus, we all know that a stable night’s sleep is an effective way of achieving healthy living. Research has proven that 90% of patients experience an increased sleeping quality and with the use of the patented sleeping aid products developed by Sleepify one can shorten the time-to-sleep, increase deep-sleep, and decrease REM-sleep.
Pictured: Rasmus Nilsson, CEO of Sleepify Medtech
The selection took place during a bootcamp in Groningen. “It was great to meet so many innovative companies”, said Rasmus. “The Go2China programme opens us up to many opportunities. China is a huge market and has a clear need for wellbeing and health solutions -Sleep is fundamental for wellbeing! We’re we’ve been selected for this programme, and we’re looking forward to the networking and partnering opportunities in China”, said Rasmus.
In its ambition to internationalise, Sleepify has been selected to take part in the EIT Health – Go2China outbound mission to Shenzhen, in November 2018. There, Sleepify will meet with distributors and healthcare professionals in order to present these sleeping solutions and to find local distributors.
The EIT Health – Go2China is a market-access and acceleration programme for EU-based health scale-ups and SMEs that want to start business activities in China, more specifically in the highly innovative Shenzhen region.
Corify Care raises €6M to revolutionise cardiac care
A significant milestone for the company.
Luminate Medical secures additional $2.5M to advance cancer care
A significant milestone for the company.
Longenesis teams up with Novartis for digital heart care innovation
Pilot project for treatment of cardiovascular diseases.